Voyager Therapeutics (NASDAQ:VYGR - Get Free Report)'s stock had its "sell (d)" rating reaffirmed by equities research analysts at Weiss Ratings in a note issued to investors on Friday,Weiss Ratings reports.
A number of other equities research analysts have also recently issued reports on the stock. Wedbush dropped their target price on shares of Voyager Therapeutics from $9.00 to $8.00 and set an "outperform" rating for the company in a research report on Thursday, August 7th. HC Wainwright reiterated a "buy" rating and set a $30.00 target price on shares of Voyager Therapeutics in a research report on Monday, September 15th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $12.96.
View Our Latest Stock Analysis on VYGR
Voyager Therapeutics Stock Performance
Shares of NASDAQ:VYGR traded up $0.10 during midday trading on Friday, reaching $4.65. 421,476 shares of the company's stock were exchanged, compared to its average volume of 578,802. The company's 50 day simple moving average is $4.28 and its two-hundred day simple moving average is $3.60. The firm has a market capitalization of $257.94 million, a PE ratio of -2.51 and a beta of 0.95. Voyager Therapeutics has a 12 month low of $2.64 and a 12 month high of $7.44.
Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.09). The business had revenue of $5.20 million for the quarter, compared to the consensus estimate of $9.50 million. Voyager Therapeutics had a negative return on equity of 37.65% and a negative net margin of 253.49%. On average, research analysts anticipate that Voyager Therapeutics will post -0.91 earnings per share for the current year.
Insiders Place Their Bets
In other Voyager Therapeutics news, CFO Nathan D. Jorgensen sold 7,666 shares of the firm's stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $4.78, for a total value of $36,643.48. Following the completion of the sale, the chief financial officer owned 123,834 shares in the company, valued at approximately $591,926.52. This trade represents a 5.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 6.39% of the company's stock.
Institutional Investors Weigh In On Voyager Therapeutics
Several hedge funds and other institutional investors have recently added to or reduced their stakes in VYGR. Allspring Global Investments Holdings LLC increased its position in Voyager Therapeutics by 53.8% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 60,462 shares of the company's stock valued at $204,000 after acquiring an additional 21,149 shares in the last quarter. CWM LLC increased its position in Voyager Therapeutics by 856.3% in the 1st quarter. CWM LLC now owns 10,471 shares of the company's stock valued at $35,000 after acquiring an additional 9,376 shares in the last quarter. Privium Fund Management B.V. acquired a new stake in Voyager Therapeutics in the 1st quarter valued at about $73,000. Invesco Ltd. increased its position in Voyager Therapeutics by 100.8% in the 1st quarter. Invesco Ltd. now owns 48,540 shares of the company's stock valued at $164,000 after acquiring an additional 24,368 shares in the last quarter. Finally, Nuveen LLC acquired a new stake in Voyager Therapeutics in the 1st quarter valued at about $368,000. Institutional investors and hedge funds own 48.03% of the company's stock.
About Voyager Therapeutics
(
Get Free Report)
Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Voyager Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Voyager Therapeutics wasn't on the list.
While Voyager Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
